Images List Premium Download Classic

Restenosis

Restenosis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Trka kinase inhibitors, compositions and methods thereof
Merck Sharp & Dohme Corp.
June 08, 2017 - N°20170158698

The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (i) (formula (i)) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal ...
Novel crystalline form of 5-chloro-n-(methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition comprising same
Legochem Biosciences,inc.
June 01, 2017 - N°20170152251

The present invention relates to a novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be ...
Coating composition and medical device
Legochem Biosciences,inc.
May 25, 2017 - N°20170143663

A coating composition for drug-eluting medical devices, which enables a medical device to be delivered to a target tissue for the purpose of treating an affected blood vessel part such as restenosis, without easy separation of a drug from the medical device during the delivery process is provided. The coating composition for drug-eluting medical devices contains a water-insoluble drug and ...
Restenosis Patent Pack
Download + patent application PDFs
Restenosis Patent Applications
Download + Restenosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Restenosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Trka kinase inhibitors, compositions and methods thereof
Msd R & D (china) Co., Ltd.
April 27, 2017 - N°20170114071

The present invention is directed to six membered heteroaryl benzamide compounds of formula (i), which are tropomyosin-related kinase (trk) family protein pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trka.
Trka kinase inhibitors, compositions and methods thereof
Merck Sharp & Dohme Corp.
April 27, 2017 - N°20170114056

The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve ...
Trka kinase inhibitors, compositions and methods thereof
Merck Sharp & Dohme Corp.
April 20, 2017 - N°20170107204

The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve ...
Restenosis Patent Pack
Download + patent application PDFs
Restenosis Patent Applications
Download + Restenosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Restenosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods and apparatus for stenting comprising enhanced embolic protection coupled with improved protections against restenosis ...
Abbott Laboratories Vascular Enterprises Limited
March 30, 2017 - N°20170086965

Apparatus and methods for stenting are provided comprising a stent attached to a porous biocompatible material that is permeable to endothelial cell ingrowth, but impermeable to release of emboli of predetermined size. Preferred stent designs are provided, as well as preferred manufacturing techniques. Apparatus and methods are also provided for use at a vessel branching. Moreover, embodiments of the present ...
Gene delivery stent using titanium oxide thin film coating and method for fabricating the same
Chonnam National University Hospital
March 23, 2017 - N°20170080131

The present invention relates to a gene delivery stent using titanium oxide thin film coating and a method for fabricating the gene delivery stent. The gene delivery stent according to the present invention may be loaded with a drug having anti-inflammatory and anti-thrombotic effects and simultaneously deliver a gene capable of inhibiting proliferation of vascular smooth muscle cells. Accordingly, late ...
Substituted pyridazines as prostacyclin receptor modulators
Arena Pharmaceuticals, Inc.
March 02, 2017 - N°20170057931

Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood ...
Variants of c-type natriuretic peptide
Biomarin Pharmaceutical Inc.
February 23, 2017 - N°20170051033

The present disclosure provides variants of c-type natriuretic peptide (cnp), pharmaceutical compositions comprising cnp variants, and methods of making cnp variants. The cnp variants are useful as therapeutic agents for the treatment of diseases responsive to cnp, including but not limited to bone-related disorders, such as skeletal dysplasias (e. G., achondroplasia), and vascular smooth muscle disorders (e. G., restenosis and ...
3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
Biomarin Pharmaceutical Inc.
February 23, 2017 - N°20170050942

(wherein r1, r2, r3, r4, r5, r6, r7, x, y and z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the ccr2 and/or ccr5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, ...
Selective inhibitors of c-fos and their antiproliferative properties
Centre National De La Recherche Scientifique(cnrs)
February 02, 2017 - N°20170029487

Selective inhibitor of c-fos and their antiproliferative properties the invention relates to selective inhibitor of c-fos for use in the prevention and/or treatment of cancers and restenosis.
5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative
Daiichi Sankyo Company, Limited
December 29, 2016 - N°20160376267

A compound represented by the general formula (i) or a pharmacologically acceptable salt thereof has an excellent lcat-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke ...
Restenosis Patent Pack
Download + patent application PDFs
Restenosis Patent Applications
Download + Restenosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Restenosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Activators of cxcr3 for the treatment of angiopathies of the eye
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
December 15, 2016 - N°20160361387

The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of c-x-c chemokine receptor 3 (cxcr3). In some embodiments, the activator of cxcr3 is interferon-γ-inducible 10 kda protein (ip-10) or a fragment or variant thereof, such as a fragment comprising or consisting ...
Hybrid stent and method of making
Abbott Cardiovascular Systems Inc.
December 01, 2016 - N°20160346102

A stent is formed by encasing or encapsulating metallic rings in an inner polymeric layer and an outer polymeric layer. At least one polymer link connects adjacent metallic rings. The stent is drug loaded with one or more therapeutic agent or drug, for example, to reduce the likelihood of the development of restenosis in the coronary arteries. The inner and ...
Compositions and methods for treating and preventing neointimal stenosis
Yale University
October 27, 2016 - N°20160310645

Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a tgfβ inhibitor, a smad2 inhibitor, an fgf receptor agonist, a let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (endo-mt) of vascular endothelial cells into smooth muscle cells (smc) at sites of endothelial damage. The disclosed methods can therefore be ...
Uses of kappa opioid synthetic peptide amides
Cara Therapeutics, Inc.
October 27, 2016 - N°20160310558

The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions ...
Cell-free tissued engineered vascular grafts
Yale University
September 22, 2016 - N°20160271152

A composition containing a macrophage inhibitor may be administered in an effective amount to prevent, inhibit or reduce restenosis, thrombus or aneurysm formation in implanted polymeric vascular grafts. The composition may be administered prior to vascular graft implantation, at the same time as vascular graft implantation, following vascular graft implantation, or any combination thereof. Examplary macrophage inhibitors include bisphosphonates, anti-folate ...
Wnt/beta-catenin inhibitor-eluting endovascular stent
Albert Einstein College Of Medicine, Inc.
September 15, 2016 - N°20160263289

A product comprising a stent for a human blood vessel which comprises (i) a scaffold which is impregnated with, adsorbed with, or coated with an inhibitor of a wnt/p-catenin pathway, or (ii) a scaffold coated with a polymer, which polymer is impregnated with, adsorbed with, or coated with an inhibitor of a wnt/p-catenin pathway, and methods of use ...
Method of producing personalized biomimetic drug-eluting coronary stents by 3d-printing
Albert Einstein College Of Medicine, Inc.
September 08, 2016 - N°20160256610

A method for using 3d printing technology produces personalized biomimetic drug-eluting coronary stent and the product thereof. The process of manufacturing stent, based on coronary angiography imaging data, measures the diameter of diseased coronary and conducts 3d reconstruction. A personalized stent for each patient according to diameter, length, and morphological characteristics of target vessel that suited to the lesion is ...
Variants of c-type natriuretic peptide
Biomarin Pharmaceutical Inc.
September 08, 2016 - N°20160256553

The present disclosure provides variants of c-type natriuretic peptide (cnp), pharmaceutical compositions comprising cnp variants, and methods of making cnp variants. The cnp variants are useful as therapeutic agents for the treatment of diseases responsive to cnp, including but not limited to bone-related disorders, such as skeletal dysplasias (e. G., achondroplasia), and vascular smooth muscle disorders (e. G., restenosis and ...
Loading